Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Diabetic vascular complications

M E Cooper1, R E Gilbert, G Jerums

  • 1Department of Medicine, University of Melbourne, Victoria, Australia.

Clinical and Experimental Pharmacology & Physiology
|October 7, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Urinary complement proteins and risk of end-stage renal disease: quantitative urinary proteomics in patients with type 2 diabetes and biopsy-proven diabetic nephropathy.

Journal of endocrinological investigation·2021
Same author

Diabetes and higher HbA1c levels are independently associated with adverse renal outcomes in inpatients following multiple hospital admissions.

Journal of diabetes and its complications·2019
Same author

Cross-sectional associations of albuminuria among Aboriginal and Torres Strait Islander adults: the eGFR Study.

Nephrology (Carlton, Vic.)·2017
Same author

Dental Decay Phenotype in Nonsyndromic Orofacial Clefting.

Journal of dental research·2017
Same author

The effects of muscle contraction and recombinant osteocalcin on insulin sensitivity ex vivo.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2015
Same author

Spectrum of Dental Phenotypes in Nonsyndromic Orofacial Clefting.

Journal of dental research·2015
Same journal

Relationship Between Long-Term Exposure to Airborne Particulate Matter and the Intrinsic Capacity of Middle-Aged and Older Adults in China: A Retrospective Cohort Study Based on CHARLS.

Clinical and experimental pharmacology & physiology·2026
Same journal

Dapagliflozin Improves Mitochondrial Function to Reduce the Risk of Atrial Fibrillation in a High-Glucose Environment by Activating the AMPK/PGC-1α/SIRT3 Signalling Pathway.

Clinical and experimental pharmacology & physiology·2026
Same journal

Hypertension-Mediated Organ Damage: Pathophysiological Mechanisms, Clinical Consequences, and Implications for Early Risk Stratification.

Clinical and experimental pharmacology & physiology·2026
Same journal

Saikosaponin D Alleviates Atherosclerosis by Regulating Autophagy and Senescence of VSMCs via Inhibiting EPHB2.

Clinical and experimental pharmacology & physiology·2026
Same journal

Noninvasively Evaluating the Cerebral Blood Flow Changes After Surgery in Adult Moyamoya Patients Using 3D Pulsed Arterial Spin Labelling MRI.

Clinical and experimental pharmacology & physiology·2026
Same journal

Targeting S100A8/A9 Ameliorates Heart Failure with Preserved Ejection Fraction by Modulating TLR4/NF-κB-Mediated Inflammation.

Clinical and experimental pharmacology & physiology·2026
See all related articles

Diabetic vascular complications, including nephropathy and heart disease, stem from metabolic and hemodynamic issues. Advanced glycation inhibition, like with aminoguanidine, shows promise in preventing these serious diabetic issues.

Area of Science:

  • Vascular biology and pathology
  • Diabetology
  • Pharmacology

Background:

  • Diabetic vascular complications are categorized into microvascular (nephropathy, retinopathy, neuropathy) and macrovascular (atherosclerosis-driven ischemic heart disease, cerebrovascular disease, peripheral vascular disease).
  • Metabolic and hemodynamic factors are believed to interact, contributing to the development of these complications.
  • Advanced glycation end-products (AGEs) are implicated in the pathogenesis of diabetic complications.

Purpose of the Study:

  • To explore the role of advanced glycation in diabetic vascular complications.
  • To evaluate the efficacy of aminoguanidine, an AGE inhibitor, in attenuating diabetic vascular complications.
  • To review the progression from experimental studies to clinical trials for therapeutic agents targeting diabetic complication pathways.

Related Experiment Videos

Main Methods:

  • Review of literature on diabetic vascular complications and pathogenesis.
  • Examination of experimental studies investigating the effects of AGE inhibition.
  • Analysis of data from large-scale clinical trials of therapeutic agents.

Main Results:

  • Advanced glycation is a significant pathway in diabetic complication development.
  • Aminoguanidine demonstrated an ability to attenuate the progression of various diabetic vascular complications in experimental models.
  • Findings from experimental studies have informed the design and execution of clinical trials.

Conclusions:

  • Targeting advanced glycation represents a promising therapeutic strategy for diabetic vascular complications.
  • Further clinical investigation is warranted to validate agents interfering with metabolic and hemodynamic pathways in diabetes management.